ProNAI defects from oligos to DDR as Sierra Oncology

January 31, 2017 Christoph Graener

Sierra Oncology president and CEO Dr. Nick Glover tells Mike Ward, Informa Pharma Intelligence insight global director of content, how the company is rebranding itself from its former incarnation ProNAI Therapeutics, armed with two in-licensed assets focused on DNA damage repair (DDR) and USD 100 million in the bank.


Previous Article
Reinventing Arena to focus on Phase II clinical candidates

Dr. Amit Munshi, new CEO of Arena Pharmaceuticals, has already made several changes in the company’s focus ...

Next Article
PhaseRx makes more noise than silence with mRNA delivery

PhaseRx president and CEO Dr. Robert Overell explains how delivering messenger RNA inside diseased cells ma...